NASDAQ:CDXC - ChromaDex Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.67
  • Forecasted Upside: -19.97 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$9.58
▼ -1.83 (-16.04%)
1 month | 3 months | 12 months
Get New ChromaDex Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CDXC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CDXC

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$7.67
▼ -19.97% Downside Potential
This price target is based on 3 analysts offering 12 month price targets for ChromaDex in the last 3 months. The average price target is $7.67, with a high forecast of $9.00 and a low forecast of $7.00. The average price target represents a -19.97% upside from the last price of $9.58.
Buy
The current consensus among 3 investment analysts is to buy stock in ChromaDex. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/11/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/10/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/9/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/7/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/5/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/4/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/2/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/4/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/2/2020OppenheimerReiterated RatingBuy$9.00High
i
Rating by Brian Nagel at Oppenheimer Holdings Inc.
11/5/2020OppenheimerReiterated RatingBuy$9.00High
i
Rating by Brian Nagel at Oppenheimer Holdings Inc.
10/12/2020HC WainwrightReiterated RatingBuy$7.00Low
i
Rating by Ram Selvaraju at HC Wainwright
10/6/2020OppenheimerBoost Price TargetOutperform$6.00 ➝ $9.00High
i
Rating by Brian Nagel at Oppenheimer Holdings Inc.
8/18/2020HC WainwrightReiterated RatingBuy$6.00 ➝ $7.00High
i
8/7/2020OppenheimerReiterated RatingBuy$6.00High
i
Rating by Brian Nagel at Oppenheimer Holdings Inc.
7/14/2020B. RileyReiterated RatingBuy$7.00Medium
i
Rating by Jeff Van Sinderen at B. Riley
5/13/2020OppenheimerInitiated CoverageBuy$6.00High
i
Rating by Brian Nagel at Oppenheimer Holdings Inc.
5/12/2020HC WainwrightReiterated RatingBuy$6.00High
i
Rating by Ram Selvaraju at HC Wainwright
4/21/2020OppenheimerReiterated RatingBuy$6.00Medium
i
3/9/2020B. RileyReiterated RatingBuyHigh
i
Rating by J. Van. Sinderen at B. Riley
2/27/2020HC WainwrightReiterated RatingBuy$6.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
1/21/2020HC WainwrightReiterated RatingBuy$6.00Low
i
Rating by Ram Selvaraju at HC Wainwright
10/15/2019OppenheimerInitiated CoverageOutperform$6.00High
i
5/28/2019HC WainwrightSet Price TargetBuy$7.00High
i
Rating by Ram Selvaraju at HC Wainwright
4/25/2019HC WainwrightReiterated RatingBuy$7.00High
i
Rating by Ram Selvaraju at HC Wainwright
3/8/2019B. RileyReiterated RatingBuyLow
i
Rating by Jeff Van Sinderen at B. Riley
2/14/2019B. RileyInitiated CoverageBuy$7.00 ➝ $7.00High
i
Rating by J. Van. Sinderen at B. Riley
1/23/2019HC WainwrightSet Price TargetBuy$7.00Low
i
Rating by Ram Selvaraju at HC Wainwright
12/10/2018HC WainwrightSet Price TargetBuy$6.00High
i
Rating by Ram Selvaraju at HC Wainwright
9/19/2018HC WainwrightSet Price TargetBuy$8.00Low
i
Rating by Ram Selvaraju at HC Wainwright
9/10/2018HC WainwrightReiterated RatingBuy$8.00High
i
Rating by Ram Selvaraju at HC Wainwright
8/7/2018HC WainwrightReiterated RatingBuy$8.00High
i
Rating by Ram Selvaraju at HC Wainwright
7/16/2018HC WainwrightSet Price TargetBuy$8.00High
i
Rating by Ram Selvaraju at HC Wainwright
6/5/2018HC WainwrightSet Price TargetBuy$8.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
5/14/2018HC WainwrightSet Price TargetBuy$8.00High
i
Rating by Ram Selvaraju at HC Wainwright
5/7/2018HC WainwrightSet Price TargetBuy$8.00Low
i
Rating by Ram Selvaraju at HC Wainwright
4/2/2018HC WainwrightSet Price TargetBuy$8.00High
i
Rating by Ram Selvaraju at HC Wainwright
3/11/2018HC WainwrightSet Price TargetBuy$8.00High
i
Rating by Ram Selvaraju at HC Wainwright
3/5/2018HC WainwrightSet Price TargetBuy$8.00Low
i
Rating by Ram Selvaraju at HC Wainwright
2/9/2018HC WainwrightSet Price TargetBuy$8.00High
i
Rating by Ram Selvaraju at HC Wainwright
1/23/2018HC WainwrightSet Price TargetBuy$8.00High
i
Rating by Ram Selvaraju at HC Wainwright
1/16/2018HC WainwrightSet Price TargetBuy$8.00High
i
Rating by Ram Selvaraju at HC Wainwright
12/15/2017HC WainwrightSet Price TargetBuy$8.00High
i
Rating by Ram Selvaraju at HC Wainwright
11/27/2017HC WainwrightBoost Price TargetBuy$6.00 ➝ $8.00Low
i
Rating by Ram Selvaraju at HC Wainwright
10/2/2017HC WainwrightReiterated RatingBuy$6.00N/A
i
Rating by R. Selvaraju at HC Wainwright
9/25/2017LADENBURG THALM/SH SHInitiated CoverageBuy ➝ Buy$7.00N/A
i
9/11/2017HC WainwrightReiterated RatingBuyN/A
i
Rating by R. Selvaraju at HC Wainwright
8/11/2017HC WainwrightSet Price TargetBuy$5.00N/A
i
3/20/2017HC WainwrightSet Price TargetBuy$6.00N/A
i
2/27/2017HC WainwrightSet Price TargetBuy$6.00N/A
i
2/16/2017HC WainwrightReiterated RatingBuy$6.00N/A
i
1/3/2017Rodman & RenshawInitiated CoverageBuy$6.00N/A
i
(Data available from 3/4/2016 forward)
ChromaDex logo
ChromaDex Corporation operates as a nutraceutical company. The company offers Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide (NAD) level used for healthy aging; and Immulina, a spirulina extract and compound, which is used for improving human immune function. It also provides reference standards and fine chemicals to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, and pharmaceutical industries. The company markets and sells its products directly in the United States and Canada; and through international distributors. ChromaDex Corporation is headquartered in Los Angeles, California.
Read More

Today's Range

Now: $9.58
$9.25
$11.55

50 Day Range

MA: $6.74
$4.59
$18.74

52 Week Range

Now: $9.58
$2.50
$23.66

Volume

3,690,033 shs

Average Volume

4,448,841 shs

Market Capitalization

$591.93 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.49

Frequently Asked Questions

What sell-side analysts currently cover shares of ChromaDex?

The following Wall Street sell-side analysts have issued reports on ChromaDex in the last twelve months: B. Riley, HC Wainwright, Oppenheimer Holdings Inc., and Zacks Investment Research.
View the latest analyst ratings for CDXC.

What is the current price target for ChromaDex?

3 Wall Street analysts have set twelve-month price targets for ChromaDex in the last year. Their average twelve-month price target is $7.67, suggesting a possible downside of 20.0%. Oppenheimer Holdings Inc. has the highest price target set, predicting CDXC will reach $9.00 in the next twelve months. B. Riley has the lowest price target set, forecasting a price of $7.00 for ChromaDex in the next year.
View the latest price targets for CDXC.

What is the current consensus analyst rating for ChromaDex?

ChromaDex currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CDXC will outperform the market and that investors should add to their positions of ChromaDex.
View the latest ratings for CDXC.

What other companies compete with ChromaDex?

How do I contact ChromaDex's investor relations team?

ChromaDex's physical mailing address is 10900 Wilshire Blvd. Suite 650, Los Angeles CA, 90024. The company's listed phone number is 310-388-6706 and its investor relations email address is [email protected] The official website for ChromaDex is www.chromadex.com.